FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 362 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Record Impact Factor for Annals of Oncology Highlights Growing Influence of... July 2, 2026 FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions December 16, 2021 Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... November 17, 2022 Load more HOT NEWS 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... Inequalities cause 2,000 extra cancer cases in Wales Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with...
